Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥14.70 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm.
July 05, 2013 at 12:00 am EDT
Share
Immuno-Biological Laboratories Co., Ltd. (JASDAQ:4570) announced a private placement with Merrill Lynch Japan Securities Co., Ltd., Investment Arm, of 70,000 units of 1st round warrants at ¥210 per unit for gross proceeds of ¥14,700,000 on June 14, 2013. The transaction has been approved at its board of directors' meeting. The warrants are exercisable into 70,000 shares of the company at an initial exercise price of ¥19,530. The subscription date is July 4, 2013, and allocation and payment date is July 5, 2013. The warrants exercise period is from July 8, 2013 to July 7, 2015. The company will incur various expenses for the issuance including attorney fee, accountant fee, judicial clerk fee, trust bank expenses and so on.
On July 5, 2013, Immuno-Biological Laboratories Co., Ltd. closed the transaction.
Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Immuno-Biological Laboratories Co., Ltd. announced that it has received ¥14.70 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm.